SECTION 1. Part B of title IV of the Public Health Service Act is amended by adding at the end the following new section: SEC. The Director of NIH, in coordination with the Directors of the National Institute of Neurological Disorders and Stroke, the National Institute of Child Health and Human Development, and such other Institutes and Centers as specified by the Director shall provide for the upgrading and unification of spinal muscular atrophy clinical trial sites and the recruitment of new investigators and sites to establish a national clinical trials network for spinal muscular atrophy. The Director of NIH, in coordination with the Directors of the National Institute of Neurological Disorders and Stroke and the National Institute of Child Health and Human Development, shall expand and intensify programs of such Institutes with respect to preclinical translation research related to spinal muscular atrophy. SEC. The Committee shall (1) share and coordinate information on existing research activities, and make recommendations to the National Institutes of Health and other Federal agencies regarding how to improve existing research programs, that are related to spinal muscular atrophy research and other related neurological diseases and disorders; (2) develop a comprehensive strategy related to spinal muscular atrophy research and other related neurological diseases and disorders and advise the National Institutes of Health and other Federal agencies, expanding proposals for collaborative, multidisciplinary research, including proposals for Common Fund research described in section 402(b)(7) and other proposals that involve collaboration between 2 or more national research institutes or national centers; (3) provide annual reports to the Secretary regarding the National Institutes of Health and other Federal agencies' collaborative multidisciplinary research efforts to support spinal muscular atrophy, including the Spinal Muscular Atrophy Project at the National Institute of Neurological Disorders and Stroke, the ongoing and future research needs to advance therapies for spinal muscular atrophy, and recommendations on how to strengthen the collaboration of research activities by the institutes and agencies to improve the results; (4) develop a summary of advances in research related to spinal muscular atrophy research and other related neurological diseases and disorders research supported or conducted by Federal agencies; and (5) not later than 1 year after the date of the establishment of the Committee, make recommendations to the Secretary (A) regarding any appropriate changes to research activities, including recommendations to improve the research portfolio of the National Institutes of Health to ensure that scientificallybased strategic planning is implemented in support of research priorities that impact research activities related to spinal muscular atrophy and other related neurological diseases and disorders; (B) identifying barriers to the development of new treatments and cures for spinal muscular atrophy and other related neurological diseases and disorders; (C) regarding public participation in decisions relating to spinal muscular atrophy research and other related neurological diseases and disorders to increase the involvement of patient advocacy and community organizations representing a broad geographical area; (D) on how best to disseminate information on spinal muscular atrophy progress; and (E) on how to expand partnerships between public entities, including Federal agencies, and private entities to expand collaborative, crosscutting research. The Committee shall be composed of the following voting members: (A) Not more than 11 voting Federal representatives as follows: (i) The Director of the Centers for Disease Control and Prevention. (ii) The Director of the National Institutes of Health and the directors of such national research institutes and national centers (which shall include the National Institute of Neurological Disorders and Stroke, the National Institute of Child Health and Human Development, and the National Center for Research Resources) as the Secretary determines appropriate.SECTION 1. Part B of title IV of the Public Health Service Act is amended by adding at the end the following new section: SEC. The Director of NIH, in coordination with the Directors of the National Institute of Neurological Disorders and Stroke, the National Institute of Child Health and Human Development, and such other Institutes and Centers as specified by the Director shall provide for the upgrading and unification of spinal muscular atrophy clinical trial sites and the recruitment of new investigators and sites to establish a national clinical trials network for spinal muscular atrophy. The Director of NIH, in coordination with the Directors of the National Institute of Neurological Disorders and Stroke and the National Institute of Child Health and Human Development, shall expand and intensify programs of such Institutes with respect to preclinical translation research related to spinal muscular atrophy. SEC. The Committee shall (1) share and coordinate information on existing research activities, and make recommendations to the National Institutes of Health and other Federal agencies regarding how to improve existing research programs, that are related to spinal muscular atrophy research and other related neurological diseases and disorders; (2) develop a comprehensive strategy related to spinal muscular atrophy research and other related neurological diseases and disorders and advise the National Institutes of Health and other Federal agencies, expanding proposals for collaborative, multidisciplinary research, including proposals for Common Fund research described in section 402(b)(7) and other proposals that involve collaboration between 2 or more national research institutes or national centers; (3) provide annual reports to the Secretary regarding the National Institutes of Health and other Federal agencies' collaborative multidisciplinary research efforts to support spinal muscular atrophy, including the Spinal Muscular Atrophy Project at the National Institute of Neurological Disorders and Stroke, the ongoing and future research needs to advance therapies for spinal muscular atrophy, and recommendations on how to strengthen the collaboration of research activities by the institutes and agencies to improve the results; (4) develop a summary of advances in research related to spinal muscular atrophy research and other related neurological diseases and disorders research supported or conducted by Federal agencies; and (5) not later than 1 year after the date of the establishment of the Committee, make recommendations to the Secretary (A) regarding any appropriate changes to research activities, including recommendations to improve the research portfolio of the National Institutes of Health to ensure that scientificallybased strategic planning is implemented in support of research priorities that impact research activities related to spinal muscular atrophy and other related neurological diseases and disorders; (B) identifying barriers to the development of new treatments and cures for spinal muscular atrophy and other related neurological diseases and disorders; (C) regarding public participation in decisions relating to spinal muscular atrophy research and other related neurological diseases and disorders to increase the involvement of patient advocacy and community organizations representing a broad geographical area; (D) on how best to disseminate information on spinal muscular atrophy progress; and (E) on how to expand partnerships between public entities, including Federal agencies, and private entities to expand collaborative, crosscutting research. The Committee shall be composed of the following voting members: (A) Not more than 11 voting Federal representatives as follows: (i) The Director of the Centers for Disease Control and Prevention. (ii) The Director of the National Institutes of Health and the directors of such national research institutes and national centers (which shall include the National Institute of Neurological Disorders and Stroke, the National Institute of Child Health and Human Development, and the National Center for Research Resources) as the Secretary determines appropriate.